tiprankstipranks
Advertisement
Advertisement

LXRX Stock Latest News

Lexicon, Novo Nordisk announce initiation of LX9851 study
The FlyLexicon, Novo Nordisk announce initiation of LX9851 study
5d ago
NVO
LXRX
Lexicon announces results from post hoc analysis on data of sotagliflozin
PremiumThe Fly
Lexicon announces results from post hoc analysis on data of sotagliflozin
17d ago
LXRX
Lexicon price target raised to $2.30 from $2.10 at Citi
PremiumThe Fly
Lexicon price target raised to $2.30 from $2.10 at Citi
18d ago
LXRX
Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones
PremiumCompany Announcements
Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones
19d ago
LXRX
Lexicon price target raised to $6 from $4 at H.C. Wainwright
PremiumThe Fly
Lexicon price target raised to $6 from $4 at H.C. Wainwright
23d ago
LXRX
Lexicon reports Q4 EPS (4c), consensus (7c)
PremiumThe FlyLexicon reports Q4 EPS (4c), consensus (7c)
23d ago
LXRX
LXRX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
LXRX Earnings this Week: How Will it Perform?
25d ago
LXRX
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing
Premium
Company Announcements
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing
2M ago
8K
LXRX
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
PremiumThe Fly
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
2M ago
V
CL
Lexicon 32M share Spot Secondary priced at $1.30
PremiumThe Fly
Lexicon 32M share Spot Secondary priced at $1.30
2M ago
LXRX
Lexicon Pharmaceuticals Launches Equity Offering to Fund Pipeline
PremiumCompany Announcements
Lexicon Pharmaceuticals Launches Equity Offering to Fund Pipeline
2M ago
8K
LXRX
Lexicon announces common stock offering, no amount given
PremiumThe Fly
Lexicon announces common stock offering, no amount given
2M ago
LXRX
Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s
PremiumThe FlyMidday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan’s
2M ago
DB
ANF
Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin
Premium
The Fly
Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin
2M ago
LXRX
Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target
Premium
Ratings
Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target
2M ago
LXRX
Lexicon Pharmaceuticals: Late-Stage Pipeline Catalysts and Strategic Partnerships Underpin Buy Rating
PremiumRatings
Lexicon Pharmaceuticals: Late-Stage Pipeline Catalysts and Strategic Partnerships Underpin Buy Rating
2M ago
LXRX
Lexicon price target raised to $2.10 from $1.90 at Citi
PremiumThe Fly
Lexicon price target raised to $2.10 from $1.90 at Citi
2M ago
LXRX
Lexicon sees cash runway into 2027
PremiumThe Fly
Lexicon sees cash runway into 2027
3M ago
LXRX
Lexicon publishes White Paper on treatments for chronic pain
PremiumThe Fly
Lexicon publishes White Paper on treatments for chronic pain
3M ago
LXRX
Lexicon Pharmaceuticals: Buy Rating Backed by Promising Cardiovascular and Neuropathic Pain Advances
PremiumRatingsLexicon Pharmaceuticals: Buy Rating Backed by Promising Cardiovascular and Neuropathic Pain Advances
4M ago
LXRX
Lexicon announces publication of preclinical data on ACSL5
Premium
The Fly
Lexicon announces publication of preclinical data on ACSL5
4M ago
NVO
LXRX
Lexicon Pharmaceuticals Files Prospectus for Stock Sale
Premium
Company Announcements
Lexicon Pharmaceuticals Files Prospectus for Stock Sale
5M ago
8K
LXRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >